
    
      About 1500 patients with staging I-III of Bladder Cancer, after accepting chemotherapy, will
      be randomly divided into group A (receive CIK treatment) or group B (just regularly follow
      up), and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK
      cells treatment (every 12 weeks). Patients in group B will have no anti-tumor therapy.
    
  